MASH

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.